LIP
PSTX

Lighthouse Investment Partners’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Lighthouse Investment Partners’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,319
Closed -$91.8K – 392
2022
Q4 		$91.8K Buy
+17,319
New +$79.2K 0.01% 227

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Lighthouse Investment Partners's PSTX Position: Q1 2023 in Review

Lighthouse Investment Partners sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2023, closing a stake of 17,319 shares — an estimated $91.8K sold.

Lighthouse Investment Partners first reported a position in PSTX in Q4 2022 and held it in 1 quarter. The position peaked at $91.8K in Q4 2022. 101 funds tracked by Wall St. Rank hold PSTX as of Q1 2023.

  • Lighthouse Investment Partners reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Lighthouse Investment Partners sold 17,319 Poseida Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $91.8K.
  • Lighthouse Investment Partners first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Lighthouse Investment Partners's Poseida Therapeutics, Inc. Common Stock position peaked at $91.8K in Q4 2022.
  • 101 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Lighthouse Investment Partners's 13F filing for Q1 2023, filed 15 May 2023.